JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
A big bank's expert decided Amneal Pharma looks like a good company again and thinks its stock could be worth $22. When smart people start believing in a company again, it can mean they see things getting better, so it's worth paying attention to what happens next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.